Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANO1 | Q5XXA6 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.42 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16112899 | 0.83 | ALDH1A1 (0.48) | ANO1CYP2C9CYP3A4CYP2C19KCNH2 | |
| SCHEMBL2839927 | 0.79 | CYP2C9 (0.46) | CYP2C9CYP3A4CYP2C19KCNH2CACNA1C | |
| SCHEMBL3395300 | 0.77 | CYP2C9 (0.47) | CYP2C9CYP3A4CYP2C19KCNH2CACNA1C | |
| SCHEMBL5514940 | 0.77 | CYP2C9 (0.45) | CYP2C9CYP3A4CYP2C19KCNH2CACNA1C | |
| SCHEMBL4758453 | 0.76 | CYP2C9 (0.50) | CYP2C9CYP3A4CYP2C19KCNH2CACNA1C | |
| SCHEMBL1918391 | 0.76 | KDM4E (0.59) | ANO1CYP3A4 | |
| SCHEMBL5514943 | 0.76 | CYP3A4 (0.52) | CYP2C9CYP3A4CYP2C19KCNH2CACNA1C | |
| SCHEMBL10240838 | 0.75 | CYP3A4 (0.47) | ANO1CYP2C9CYP3A4CYP2C19KCNH2 | |
| SCHEMBL2841670 | 0.75 | CYP2C9 (0.42) | CYP2C9CYP3A4CYP2C19KCNH2CACNA1C | |
| SCHEMBL2837609 | 0.75 | ANO1 (0.55) | ANO1CYP3A4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040162318-A1 | Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis C viral infections and associated diseases | VIROPHARMA INCORPORATED | 2004-08-19 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040162318-A1 | Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis C viral infections and associated diseases | BBOX1, HAVCR2, CYP2E1 | ANO1 3901/4885CYP2C9 129/4885CYP3A4 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.